approach. After implementation, our patient partners were consulted again. They felt that implementation of the PASDAS and skin scores significantly improved the evaluation of disease activity on all domains, and this was highly appreciated. Future improvements might include additional optimisation of the PASDAS by reducing the number of questions and using only licence-free measurement instruments.

Acknowledgements

AbbVie provided financial support for the project Implementation Integral Psoriatic Arthritis Information System. AbbVie had no influence on the content of this letter.

Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this letter.

Disclosure statement: The authors have declared no conflicts of interest.

Michelle L. M. Mulder1, Alfons A. den Broeder1,2, Berbke T. J. van Ginneken1, Elien A. M. Mahler1, Frank H. J. van den Hoogen1,2, Johanna E. Vriezekolk1 and Mark H. Wenink1

1Department of Rheumatology, Sint Maartenskliniek and 2Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands

Accepted 24 May 2019
Correspondence to: Michelle L. M. Mulder, Sint Maartenskliniek, Department of Rheumatology, PO Box 9011, 6500 GM, Nijmegen, The Netherlands.
E-mail: m.mulder@maartenskliniek.nl

References

1 Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499–510.
2 Coates LC, Moverley AR, McParland L et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015;386:2489–98.
3 Coates LC, Helliwell PS. Treating to target in psoriatic arthritis: how to implement in clinical practice. Ann Rheum Dis 2016;75:640–3.
4 Coates LC, FitzGerald O, Merola JF et al. Group for research and assessment of psoriasis and psoriatic arthritis/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol 2018;70:345–55.
5 Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int 2014;2014:1
6 Helliwell PS, FitzGerald O, Fransen J et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE Project). Ann Rheum Dis 2013;72:396–91.
7 Helliwell PS, Waxman R. Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS). Ann Rheum Dis 2018;77:467–8.
8 Coates LC. Implementing the findings of the TICOPA trial in clinical practice: challenges in implementation and how information technology can bridge the gap. Clin Exp Rheumatol 2016;34(5 Suppl 101):S73–S74.

Sir, The 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) were developed to identify homogeneous populations of IIM patients for research purposes [1, 2]. The presence or absence of certain disease features contribute to an IIM probability score, with >50% indicating ‘possible’, >55% ‘probable’ and >90% ‘definite’ IIM. Using the ‘probable IIM’ probability cut-off, sensitivity remains high (93%) [1]. However, while classification as ‘definite IIM’ is the suggested threshold for inclusion in studies where high specificity levels are required, sensitivity is lower (around 70%), limiting the number of patients eligible for enrolment [1]. Those with ‘definite IIM’ or ‘probable IIM’ can be further distinguished using a classification tree into one of four IIM subtypes: PM, IBM, amyopathic dermatomyositis and DM. As immune-mediated necrotizing myopathy (IMNM) was only recently recognized as a distinct entity, only small numbers of these cases were included in the classification design process. The authors were thus unable to distinguish PM from IMNM in the classification tree [1, 3].

As highlighted by Lundberg and Tjärnlund, another limitation of the criteria is the limited use of myositis-specific autoantibodies (MSAs), with only anti-Jo1 status included in the final criteria [4]. As the project to define these criteria commenced over a decade ago, many MSAs were either undiscovered or their detection assays were not widely accessible, preventing inclusion [1, 4]. However, recent years have seen a revolution in the availability of MSA testing, with highly specific and reliable line blot immunoassays commercially available and able to test for a broad complement of MSAs simultaneously.

It is considered that integration of a wider repertoire of MSAs into updated classification criteria might improve
IIM: idiopathic inflammatory myopathy; MSA: myositis-specific autoantibody.

**Table 1** The relationship between EULAR/ACR classification criteria with and without inclusion of non-anti-Jo1 MSAs

| Current classification | Definite IIM | Probable IIM | Possible IIM | Non-IIM | Totals |
|------------------------|-------------|--------------|-------------|--------|--------|
| Definite IIM           | 57          | 0            | 0           | 0      | 57 (73.1%) |
| Probable IIM           | 13          | 0            | 0           | 0      | 13 (16.7%) |
| Possible IIM           | 0           | 0            | 0           | 0      | 0      |
| Non-IIM                | 5           | 3            | 0           | 0      | 8 (10.3%) |
| Totals                 | 75 (96.2%)  | 3 (3.8%)     | 0           | 0      |        |

IIM: idiopathic inflammatory myopathy; MSA: myositis-specific autoantibody.

performance both in terms of case definition and in assigning IIM subtype. To evaluate this, we conducted a study of patients in our IIM cohort where a panel of MSA results, in addition to anti-Jo1, were available. We identified all adult patients (≥18 years at disease onset) with a physician-verified diagnosis of IIM. Details of data source and case ascertainment are available in the supplementary material, section Case ascertainment, available at Rheumatology online. The EULAR/ACR criteria were applied to each case and results were categorized using the suggested cut-points into non-IIM, possible IIM, probable IIM and definite IIM. We then identified all patients with a non-anti-Jo1 MSA including anti-PL7, anti-PL12, anti-EJ, anti-OJ, anti-Mi2, anti-MDA5, anti-SAE1, anti-transcription intermediary factor 1γ, anti-NXP2 and anti-signal recognition particle using a line blot immunoassay (EUROLINE Inflammatory Myopathies 16 Ag, Euroimmun, Lubeck, Germany). This assay has not been fully validated yet, but has high reported specificity for IIM [5]. Anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase was also identified via ELISA. The same criteria including classification tree were then reapplied, with the non-anti-Jo1 MSAs assigned the same weight as an anti-Jo1 antibody.

We identified 309 patients with an average age of 55.6 years, of whom 62.8% were female. Of these, 27/309 (8.7%) possessed anti-Jo1 antibodies, while 78/309 (25.2%) were negative for anti-Jo1 antibodies, but had an alternative MSA. This work forms part of a national quality improvement project aimed at accurate identification of IIM cases for development of specialized disease commissioning and service planning. Given this context, approval for the conduct of the project was granted without a recommendation to seek more formal ethics authorization. In the non-anti-Jo1 MSA-positive subgroup, according to the EULAR/ACR criteria, 57/78 (73.1%) had ‘definite IIM’, 13/78 (16.7%) ‘probable IIM’, 0/78 ‘possible IIM’ and 8/78 (10.3%) ‘non-IIM’. When other MSAs were given the same weight as an anti-Jo1 in the antibody criterion, classification of definite IIM increased to 75/78 (96.2%) patients. Those with probable IIM reduced to 3/78 (3.8%) and no patients were defined as ‘non-IIM’ (Table 1).

Currently, MSAs are not included in the classification tree used to define IIM subtypes. In our cohort, 25/78 (32.1%) patients were subtyped as PM and had an MSA other than anti-Jo1. Fifteen of 78 (19.2%) patients had a diagnosis of IMNM with either anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase or anti-signal recognition particle antibodies and met 2017 European Neuromuscular Centre criteria for IMNM [3]. A further 8/78 (10.3%) cases had antisynthetase syndrome with a relevant antisynthetase antibody. One of 78 (1.3%) patients had dermatomyositis sine dermatitis with an anti-NXP2 antibody.

We highlight improved performance of the EULAR/ACR classification criteria after inclusion of widely available MSA results, building on the experience of others who have examined the effect of including antisynthetase antibodies [6]. We have demonstrated that including non-anti-Jo1 MSAs increases the likelihood of classifying patients as ‘definite IIM’ or ‘probable IIM’, facilitating accurate diagnosis and inclusion of patients into clinical trials and research studies. Additionally, inclusion of MSAs into the classification tree can more precisely define IIM subtypes, reducing the number of patients incorrectly classified as PM and potentially supporting the use of targeted treatments for individual subgroups and facilitating accurate inclusion in subgroup-specific clinical trials. We suggest that an additional layer of the classification tree referring to MSA status is added at the point where patients are currently subtyped as PM. Elements from the 2017 European Neuromuscular Centre criteria for IMNM may be integrated into this. Limitations to the study include its retrospective single-centre design and the absence of a comparator group. Finally, the specificities of all MSAs are not yet fully determined [7].

**Funding:** This work was supported by a grant from the Medical Research Council (MR/N003322/1). This report includes independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health.

**Disclosure statement:** The authors have declared no conflicts of interest.

**Supplementary data**

Supplementary data are available at Rheumatology online.
Rheumatology 2019;58:2333–2335
doi:10.1093/rheumatology/kez229
Advance Access publication 26 June 2019

Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis

Rheumatology key message

- Guideline adherence in the management of cardiovascular risk should be improved in ANCA-associated vasculitis.

Sr, the ANCA-associated vasculitides (AAV) are rare inflammatory diseases. For the most common subtype (granulomatosis with polyangiitis), the estimated prevalence varies between 2.3 per million in Japan and 160 per million in Sweden [1]. Several studies have reported that patients with AAV are at increased risk of accelerated atherosclerosis and have an excess cardiovascular (CV) risk of ~65% [2, 3]. Therefore, the EULAR and the Canadian Vasculitis research network (CanVasc) guidelines for AAV recommend annual review of traditional CV risk factors [4, 5]. Awareness of the prevalence of CV risk factors in AAV, including markers of inflammation and chronic kidney disease, and their optimal management may improve the long-term outcomes of patients with AAV. We examined the prevalence of CV risk factors in patients with AAV and evaluated adherence to current CV risk management guidelines in the Netherlands and Canada.

We conducted an international, two-centre, cross-sectional study of prevalent patients diagnosed with AAV >3 months who were >18 years of age. Eligible patients were recruited from the Northwest Clinics in the Netherlands (a community hospital in Den Helder and a teaching hospital in Alkmaar) from October 2016 to May 2017, and the Mount Sinai Hospital Vasculitis Clinic, a tertiary referral centre in Toronto, Canada, from July to October 2018. The study was approved by the Medical Ethical Committee in both countries and performed in accordance with the Declaration of Helsinki.

Demographic and disease characteristics at the time of the study were collected. A comprehensive CV risk assessment was performed in all patients and included a history of CV disease and a physical examination. Blood pressure was recorded twice, non-invasively in the left arm, and the mean of two measurements was calculated. Hypertension was defined as a blood pressure >140/90 mmHg and/or the use of antihypertensive therapy. Dyslipidaemia was defined as low-density lipoprotein cholesterol levels >2.5 mmol/l and/or the use of lipid lowering therapy. Laboratory tests that were collected included immunoassays for the detection of ANCA to proteinase-3 and myeloperoxidase, CRP, serum creatinine,